1. Home
  2. TC vs INTS Comparison

TC vs INTS Comparison

Compare TC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TuanChe Limited

TC

TuanChe Limited

N/A

Current Price

$7.57

Market Cap

29.0M

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.40

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TC
INTS
Founded
2010
2012
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.0M
24.0M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
TC
INTS
Price
$7.57
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.33
AVG Volume (30 Days)
14.4K
2.2M
Earning Date
12-16-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,115,721.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.50
$0.19
52 Week High
$39.00
$3.17

Technical Indicators

Market Signals
Indicator
TC
INTS
Relative Strength Index (RSI) 25.13 46.98
Support Level $6.70 $0.39
Resistance Level $7.94 $0.41
Average True Range (ATR) 1.10 0.03
MACD -0.05 -0.00
Stochastic Oscillator 14.67 43.14

Price Performance

Historical Comparison
TC
INTS

About TC TuanChe Limited

Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: